The aim of the study is to evaluate the efficacy and tolerability of the five triptans that are commercially available in Italy (zolmitriptan 2.5 mg, rizatriptan 10 mg, sumatriptan 100 mg, almotriptan 12.5 mg and eletriptan 40 mg). The study was conducted in single-blind versus placebo and its duration was 18 months. At the Headache Centre of the 'Agostino Gemelli' Hospital in Rome we selected 42 patients, suffering from headache with and without aura (International Headache Society Committee on Headache Classification, 1988 Cephalalgia 8:1-96), whose headache frequency ranged between 1- and 4-monthly crises. For a total of 25 crises, for every five consecutive crises, a different triptan was taken. The end-points of the study were as follows: response at 2 h, 'pain free' at 2 h and 'sustained pain free' (at 24 h). The intra-patient consistency and the tolerability were also evaluated. Thirty patients completed the study and the statistical analysis was only applied to these patients. No substantial difference in terms of the efficacy of the triptans was noted; all triptans were well tolerated. These results suggest the possibility of testing different triptans in the same patient in order to identify the ideal drug for every patient. © 2005 EFNS.

Multiple attack study on the available triptans in Italy versus placebo / Vollono, C.; Capuano, A.; Mei, D.; Ferraro, Diana; Pierguidi, L.; Evangelista, M.; Di Trapani, Girolamo. - In: EUROPEAN JOURNAL OF NEUROLOGY. - ISSN 1351-5101. - 12:7(2005), pp. 557-563. [10.1111/j.1468-1331.2005.01030.x]

Multiple attack study on the available triptans in Italy versus placebo

FERRARO, Diana;
2005

Abstract

The aim of the study is to evaluate the efficacy and tolerability of the five triptans that are commercially available in Italy (zolmitriptan 2.5 mg, rizatriptan 10 mg, sumatriptan 100 mg, almotriptan 12.5 mg and eletriptan 40 mg). The study was conducted in single-blind versus placebo and its duration was 18 months. At the Headache Centre of the 'Agostino Gemelli' Hospital in Rome we selected 42 patients, suffering from headache with and without aura (International Headache Society Committee on Headache Classification, 1988 Cephalalgia 8:1-96), whose headache frequency ranged between 1- and 4-monthly crises. For a total of 25 crises, for every five consecutive crises, a different triptan was taken. The end-points of the study were as follows: response at 2 h, 'pain free' at 2 h and 'sustained pain free' (at 24 h). The intra-patient consistency and the tolerability were also evaluated. Thirty patients completed the study and the statistical analysis was only applied to these patients. No substantial difference in terms of the efficacy of the triptans was noted; all triptans were well tolerated. These results suggest the possibility of testing different triptans in the same patient in order to identify the ideal drug for every patient. © 2005 EFNS.
12
7
557
563
Multiple attack study on the available triptans in Italy versus placebo / Vollono, C.; Capuano, A.; Mei, D.; Ferraro, Diana; Pierguidi, L.; Evangelista, M.; Di Trapani, Girolamo. - In: EUROPEAN JOURNAL OF NEUROLOGY. - ISSN 1351-5101. - 12:7(2005), pp. 557-563. [10.1111/j.1468-1331.2005.01030.x]
Vollono, C.; Capuano, A.; Mei, D.; Ferraro, Diana; Pierguidi, L.; Evangelista, M.; Di Trapani, Girolamo
File in questo prodotto:
File Dimensione Formato  
multiple attack.pdf

non disponibili

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 164.68 kB
Formato Adobe PDF
164.68 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1141688
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 8
social impact